17,261 trials
Kidney Transplant · Adult Living Donor Kidney Transplant Recipients · Renal Transplant
Primary: Incidence of Banff 2A or Higher Acute Cell-mediated Rejection and/or Acute Antibody Mediated Rejection — 0; 0; 0 Participants
Shock, Septic
Primary: Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study Completion — 12; 12; 11; 10 Participants
COVID-19
Primary: Change From Baseline to Day 5 in Viral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribonucleic Acid (RNA) Level in Nasopharyngeal (NP) Swabs: mITT…
Hepatocellular Carcinoma
Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001
Metastatic Melanoma · Stage III Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Number of Participants With Immune-Related Response — 8 Participants
Suspected or Confirmed COVID-19
Primary: Amplicon Sequence Variants (ASVs) That Are Significantly Correlated With Variation in the Microbiome Data Between NBT-NM108 Group and Usual Care Only Group From Day 0 to…
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Stage III Non-small Cell Lung Cancer · Unresectable
Primary: Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents — 23.9; 35.0; 40.3 Percentage of…
Hypertension · Hypertension,Essential
Primary: Changes in Systolic Ambulatory Blood Pressure — -1.4; -2.9 mmHg — p=0.2682
Multiple Myeloma
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 7; 7; 8 Participants
Acromegaly
Primary: Percent Change in Insulin-like Growth Factor I (IGF-1) From Baseline to Week 27 — -6.20; -7.16; -7.09 Percent change
Pulmonary Sarcoidosis
Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804
Prostate Cancer
Primary: Percentage of Participants With Histologically Positive Lesions That Are Positive on Imaging — 86 % of participants with + lesions
GVHD · Hematologic Neoplasms
Primary: Occurrence of Moderate and Severe Chronic GVHD at One Year Post Transplant — 0; 8 Participants
Atopic Dermatitis · Plaque Psoriasis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=)…